A report, launched by Takeda UK, has shown that despite the increase in media attention, COVID-19 has had little positive impact on the perception of pharmaceutical companies.
A report, launched by Takeda UK, has shown that despite the increase in media attention, COVID-19 has had little positive impact on the perception of pharmaceutical companies. The results of the report were revealed in a Dec. 10, 2020 press release.
The report has been formulated based on online interviews, performed by Ipsos MORI on behalf of Takeda UK, with UK adults aged between 16 and 75 years. In total, 1104 interviews were performed during October 2020.
Key results of the survey include: 17% of respondents indicated their perception of pharmaceutical companies had improved based on the reaction of the industry to COVID-19; 54% of respondents had no change of opinion; and 16% of respondents stated that their impression had worsened. When asked for their opinion on pharmaceutical companies, only 38% responded favorably, and only 48% of respondents stated that they trusted the pharma industry to act in the best interest of society.
“The pharmaceutical industry has faced several reputational challenges over the years. However, perhaps now more than ever, the development of new treatments relies on cross-sector collaborations and public trust and willingness to engage with the sector,” said Jon Neal, managing director, UK and Ireland at Takeda, in the press release. “Therefore, we need to address perceptions of the industry to improve the future of healthcare and ultimately save lives. We hope this report will lead to further discussion about how the industry can convey a stronger purpose to build trust with both patients and other healthcare organizations.”
Ben Page, CEO of Ipsos MORI, added, in the press release, “Our research with Takeda suggests that the public have a higher opinion of roles or organizations that articulate a strong purpose around their role in and value to society. The pharmaceutical industry has historically struggled to clearly articulate what it does and what it stands for. If the sector wants to better connect with the public, it needs to start talking much more openly about its activities and values.”
The full report—Pharma Repurposed?—is available from Takeda UK.
Source: Takeda
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.